Shared on22 Oct 25
Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.
Shared on08 Oct 25Fair value Increased 2.96%
Analysts have raised their price target for Avadel Pharmaceuticals from $20.30 to $20.90, citing continued commercial momentum for Lumryz. However, they note this optimism is tempered by competitive and market uncertainties.
Shared on23 Sep 25Fair value Increased 0.50%
Analysts marginally raised Avadel Pharmaceuticals’ price target to $20.30, citing strong commercial execution and growing Lumryz adoption, while noting competitive risks may limit upside. Analyst Commentary Bullish analysts highlight that commercial investments are delivering tangible benefits, evidenced by improved persistency and an expanding number of reimbursed Lumryz patients.
Shared on08 Sep 25Fair value Increased 6.32%
Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted. Analyst Commentary Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.
Shared on24 Aug 25Fair value Increased 4.11%
The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.
Shared on09 Aug 25Fair value Increased 5.80%
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.
Shared on01 Aug 25
As Avadel Pharmaceuticals’ consensus analyst price target, future P/E, and consensus revenue growth forecasts all remained effectively unchanged, the fair value assessment holds steady at $17.25. What's in the News ASL Strategic Value Fund LP has urged shareholders to vote against Avadel's board nominees and called for an independent election monitor at the upcoming annual meeting, citing concerns about past vote counting procedures.